Best practices for developing single-use TFF steps for biopharmaceuticals
From filter selection to GMP implementation
Tangential flow filtration is commonly used in bioprocessing for applications such as process steam clarification, cell therapy harvests, protein concentration and diafiltration. Applying single-use technologies to this step confers significant benefits including increasing flexibility and reducing time to market through the elimination of cleaning and validation programs.
In this webinar you will learn how to select, size and scale the most appropriate TFF filter for your application. Critically this ensures both development and subsequent manufacturing costs are optimized. We will describe how the selected filter must be integrated into a single-use manifold in such a way that automation can be applied to ensure process consistency and control.
You will learn what points should be considered in determining the level of automation required for your applications such as operational preferences and the environment in which the equipment will be used. We will describe the sophisticated control strategies and innovative process analytical technolgies (PAT) such as GMP-ready, single-use sensors that can be integrated into single-use TFF steps. These technologies can greatly enhance control and thereby reduce the cost of poor quality associated with the closing of deviations prior to lot release.
Watch this webinar on demand now if you are considering or in the process of implementing single-use TFF operations within your bioprocess.
Understand the benefits of single-use TFF technologies
Learn how to correctly select, size and scale TFF filters for single-use applications
Learn how to determine the optimum single-use TFF automation strategy
Understand how single-use sensor technology can be applied to enhance process control
Global Market Development Manager
Parker domnick hunter, UK
Dr Nick Hutchinson has a masters and Doctorate in Biochemical Engineering from University College London, UK, where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in a R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA.
Nick now works in Market Development at Parker domnick hunter where his focus is on bringing Parker's strengths in motion and control to bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.